Category - Developments

Developments

MOA of Can-Fite’s CF602 can improve sexual dysfunction

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has reported new findings for its CF602 drug candidate showing a defined mechanism of action in erectile dysfunction similar to sildenafil (Viagra) in a rat model of...

October 22, 2015

Developments

Obama to expand MAT in opioid addiction

President Barack Obama has tackled the opioid epidemic this week by telling health care providers across the country that access to medication-assisted treatment (MAT) must be expanded. He released an order giving...

October 22, 2015

Developments

Viking Therapeutics posts positive VK5211 results

Viking Therapeutics (NASDAQ:VKTX) has successfully completed a short-term safety, tolerability, and pharmacokinetic study of VK5211 in healthy elderly subjects. VK5211 is in development for the treatment of patients...

October 20, 2015

Developments

Profound Medical presents TULSA-PRO data

Twelve-month data from Profound Medical’s (TSXV:PRN) Phase 1 clinical trial of its TULSA-PRO medical device were presented at the European Symposium on Focused Ultrasound Therapy in London. TULSA is a minimally invasive...

October 16, 2015

Developments

Transition Therapeutics to pursue Phase 3 program in AD

Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has completed a thorough review of the data from a Phase 2/3 study of ELND005 in Alzheimer’s disease (AD) patients with moderate or severe agitation and aggression. The...

October 15, 2015

Developments

Can-Fite BioPharma in registered direct offering

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has entered into definitive agreements with existing institutional investors to receive gross proceeds of about $4.8-million. The company will issue 1,109,196 registered...

October 13, 2015

Developments

EMA grants orphan designation to Can-Fite’s CF102

Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) oncology drug candidate, CF102, has been granted orphan drug designation by the European Medicines Agency (EMA) for the indication of hepatocellular carcinoma (HCC), the...

October 12, 2015

Developments

Dipexium hits 50% enrollment in second Phase 3 trial

Dipexium Pharmaceuticals’ (NASDAQ: DPRX) OneStep-2 pivotal Phase 3 clinical trial has reached the 50% enrollment milestone. OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials, with 180 patients in...

October 1, 2015

Developments

Cellectar gets NCI grant for PDC platform

Cellectar Biosciences (NASDAQ:CLRB) has received initial notice of award for a Phase I-II Fast-Track Small Business Innovation Research (SBIR) grant. The SBIR grant provides up to $2.3-million over 2 1/2 years from the...

October 1, 2015

Developments

Novadaq, Arthrex to sell combined endoscopic system

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has entered into a co-marketing agreement with Arthrex, a global medical device company and leader in orthopedic medical device innovation. The agreement allows the two...

October 1, 2015

Category - Developments

MOA of Can-Fite’s CF602 can improve sexual dysfunction

Obama to expand MAT in opioid addiction

Viking Therapeutics posts positive VK5211 results

Profound Medical presents TULSA-PRO data

Transition Therapeutics to pursue Phase 3 program in AD

Can-Fite BioPharma in registered direct offering

EMA grants orphan designation to Can-Fite’s CF102

Dipexium hits 50% enrollment in second Phase 3 trial

Cellectar gets NCI grant for PDC platform

Novadaq, Arthrex to sell combined endoscopic system

General

More